Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

A review of perspectives on the use of randomization in phase II oncology trials

Grayling, Michael J, Dimairo, Munyaradzi, Mander, Adrian P ORCID: https://orcid.org/0000-0002-0742-9040 and Jaki, Thomas F 2019. A review of perspectives on the use of randomization in phase II oncology trials. JNCI: Journal of the National Cancer Institute 111 (12) , pp. 1255-1262. 10.1093/jnci/djz126

[thumbnail of djz126.pdf]
Preview
PDF - Accepted Post-Print Version
Available under License Creative Commons Attribution.

Download (633kB) | Preview

Abstract

Historically, phase II oncology trials assessed a treatment’s efficacy by examining its tumor response rate in a single-arm trial. Then, approximately 25 years ago, certain statistical and pharmacological considerations ignited a debate around whether randomized designs should be utilized instead. Here, based upon an extensive literature review, we review the arguments on either side of this debate. In particular, we describe the numerous factors that relate to the reliance of single-arm trials on historical control data, and detail the trial scenarios in which there was general agreement on preferential utilization of single-arm or randomized design frameworks, such as the use of single-arm designs when investigating treatments for rare cancers. We then summarize the latest figures on phase II oncology trial design, contrasting current design choices against historical recommendations on best practice. Ultimately, we find several ways in which the design of recently completed phase II trials does not appear to align with said recommendations. For example, despite advice to the contrary, only 66.2% of the assessed trials that employed progression-free survival as a primary or co-primary outcome used a randomized comparative design. In addition, we identify that just 28.2% of the considered randomized comparative trials came to a positive conclusion, as opposed to 72.7% of the single-arm trials. We conclude by describing a selection of important issues influencing contemporary design, framing this discourse in light of current trends in phase II, such as the increased use of biomarkers and recent interest in novel adaptive designs.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Centre for Trials Research (CNTRR)
Publisher: Oxford University Press (OUP): Policy B - Oxford Open Option D
ISSN: 0027-8874
Date of First Compliant Deposit: 23 July 2019
Date of Acceptance: 12 June 2019
Last Modified: 08 Nov 2023 13:32
URI: https://orca.cardiff.ac.uk/id/eprint/124445

Citation Data

Cited 34 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item

Downloads

Downloads per month over past year

View more statistics